+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: An open label pilot study



Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: An open label pilot study



Cephalalgia 22(4): 309-312



Rizatriptan is an effective and fast acting drug for the acute treatment of migraine. As with any other acute treatment for migraine, headache recurrence may occur in up to one-third of responders. Combination with non-steroidal anti-inflammatory drugs (NSAIDs) seems to reduce the incidence of headache recurrence in clinical practice. Rofecoxib is a member of a new class of NSAIDs, which selectively inhibits the COX-2 enzyme and therefore is associated with a lower risk of gastrointestinal side-effects; the drug has a long plasma half-life (17 h). This open label study compared rizatriptan with rizatriptan plus rofecoxib in the acute treatment of migraine. Fifty-six triptan naive patients from a tertiary centre (37 women and 19 men, ages 16-55 years, mean 35 years) with International Headache Society migraine were randomized into two groups. They were instructed to treat three consecutive moderate or severe attacks with either 10 mg rizatriptan (group 1: 18 women and 10 men) or with 10 mg rizatriptan plus 25 mg rofecoxib (group 2: 19 women and 9 men). The presence of headache and nausea at 1, 2 and 4 h, and of side-effects, use of rescue medication and recurrence were compared. Fifty-four patients completed the study. Group 1 treated 76 attacks and group 2 treated 81 attacks. Absence of headache at 1 h was seen in 19 attacks (25%) in group 1 and in 34 attacks (42%) in group 2 (P = 0.082); at 2 h absence of headache was seen in 60% of group 1 attacks and in 76% of group 2 attacks (P = 0.115). At 4 h, 75% of group 1 attacks and 88% of group 2 attacks were pain free (P = 0.122). With regard to nausea, of those who had nausea at baseline, 31% and 49% of attacks in groups 1 and 2, respectively, were nausea free at 1 h (P = 0.091), 75% and 79% at 2 h (P = 0.736) and 82% and 91% (P = 0.479) at 4 h. Recurrence, based on all attacks of those patients who achieved pain free at 4 h, was observed in 53% of group 1 and 20% of group 2 attacks (P < 0.001). Sustained pain-free rates (for the 4-h time point) were 45.6% of group 1 and 78.9% of group 2 attacks. There were no significant differences with regard to rescue medication consumption after 4 h and side-effects in both groups. There was a non-significant trend for the combination group to have a higher response rate. The group treated with rizatriptan and rofecoxib had a lower recurrence rate than the group treated with rizatriptan. This study demonstrated that combining a fast acting triptan such as rizatriptan with rofecoxib reduced headache recurrence rates, was well tolerated and may be more effective than the use of rizatriptan alone. Double-blind, placebo-controlled studies are necessary to confirm these observations.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011307236

Download citation: RISBibTeXText

PMID: 12100094

DOI: 10.1046/j.1468-2982.2002.00369.x


Related references

Rizatriptan in migraine. Expert Review of Neurotherapeutics 5(5): 597-603, 2005

Patient preference in a crossover clinical trial of patients with osteoarthritis of the knee or hip: face validity of self-report questionnaire ratings. Journal of Rheumatology 32(3): 533-539, 2005

Rizatriptan in treating migraine: a multicenter, double-blind randomized placebo controlled clinical trial. Zhongguo Xinyao yu Linchuang Zazhi 24(3): 219-222, 2005

Rizatriptan. Neurologia 15(1): 22-30, 2000

Rizatriptan tablet versus wafer: patient preference. Headache 40(5): 371-372, 2000

Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis. PharmacoTherapy 22(1): 1-5, 2002

Efficacy and tolerability of clomipramine, pirlindole and escitalopram in the treatment of neurotic level depression. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 108(3): 29-32, 2008

Rizatriptan 10-mg wafer versus usual nontriptan therapy for migraine: analysis of return to function and patient preference. Headache 45(9): 1140-1150, 2005

Acute treatment of migraine attacks Efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. Cephalalgia. : 232-240,, 1999

Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Current Medical Research and Opinion 18(3): 129-138, 2002

Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants. Antimicrobial Agents and ChemoTherapy 37(6): 1214-1218, 1993

Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. Bju International 97(3): 540-546, 2006

Cluster-like headache secondary to parasagittal hemangiopericytoma. Headache 53(9): 1496-1498, 2013

Efficacy of rituximab treatment and further courses of treatment in patients with rheumatoid arthritis is not dependent on rheumatoid factor seroreversion. 2006

Cluster headache in the United States of America: demographics, clinical characteristics, triggers, suicidality, and personal burden. Headache 52(1): 99, 2012